The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lüneburg, Nicole ^a   Harbaum, Lars ^a   Hennigs, Jan K ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N N DIMETHYLARGININE; ARGININE; DIMETHYLARGININASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; OXYGEN; PROTEIN ARGININE METHYLTRANSFERASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; AMIDASE; N,N-DIMETHYLARGININE;

ASTHMA; CELL FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME DEGRADATION; FIBROSING ALVEOLITIS; HYPOXIA; LUNG CANCER; PULMONARY HYPERTENSION; REGULATORY MECHANISM; RESPIRATORY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SLEEP DISORDERED BREATHING; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; CHRONIC DISEASE; HUMAN; METABOLISM; RESPIRATORY TRACT DISEASE;

AMIDOHYDROLASES; ANIMALS; ANOXIA; ARGININE; CHRONIC DISEASE; HUMANS; NITRIC OXIDE; RESPIRATORY TRACT DISEASES;

EID: 84897822982     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/501612     Document Type: Review

References (128)

1. Moncada S., Higgs A., The L-arginine-nitric oxide pathway. The New England Journal of Medicine 1993 329 27 2002 2012 2-s2.0-0027752805 10.1056/NEJM199312303292706 (Pubitemid 24015045)
2. Michel T., Feron O., Nitric oxide synthases: which, where, how, and why? The Journal of Clinical Investigation 1997 100 9 2146 2152 2-s2.0-0030711558
3. Bredt D. S., Glatt C. E., Hwang P. M., Fotuhi M., Dawson T. M., Snyder S. H., Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 1991 7 4 615 624 2-s2.0-0025941639 10.1016/0896-6273(91)90374-9
4. Lowenstein C. J., Glatt C. S., Bredt D. S., Snyder S. H., Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proceedings of the National Academy of Sciences of the United States of America 1992 89 15 6711 6715 2-s2.0-0026729267 10.1073/pnas.89.15.6711
5. Sase K., Michel T., Expression and regulation of endothelial nitric oxide synthase. Trends in Cardiovascular Medicine 1997 7 1 28 37 2-s2.0-0031017769 10.1016/S1050-1738(96)00121-1 (Pubitemid 27086336)
6. Wilcox J. N., Subramanian R. R., Sundell C. L., Ross Tracey W., Pollock J. S., Harrison D. G., Marsden P. A., Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 11 2479 2488 2-s2.0-0031444666 (Pubitemid 28015984)
7. Moncada S., Palmer R. M. J., Higgs E. A., Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991 43 2 109 142 2-s2.0-0025883342
8. Semenza G. L., Mechanisms of disease: oxygen sensing, homeostasis, and disease. The New England Journal of Medicine 2011 365 6 537 547 2-s2.0-80051625243 10.1056/NEJMra1011165
9. Ho J. J., Man H. S., Marsden P. A., Nitric oxide signaling in hypoxia. Journal of Molecular Medicine 2012 90 217 231
10. Howell K., Costello C. M., Sands M., Dooley I., McLoughlin P., L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. The American Journal of Physiology-Lung Cellular and Molecular Physiology 2009 296 6 L1042 L1050 2-s2.0-67049099308 10.1152/ajplung.90327.2008
11. Tran C. T. L., Leiper J. M., Vallance P., The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements 2003 4 4 33 40 2-s2.0-1242273847 10.1016/S1567-5688(03)00032-1 (Pubitemid 38234493)
12. Leiper J., Vallance P., Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovascular Research 1999 43 3 542 548 2-s2.0-0033566683 10.1016/S0008-6363(99)00162-5 (Pubitemid 29369253)
13. Druhan L. J., Forbes S. P., Pope A. J., Chen C.-A., Zweier J. L., Cardounel A. J., Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry 2008 47 27 7256 7263 2-s2.0-46849095596 10.1021/bi702377a (Pubitemid 351956374)
14. Strobel J., Mieth M., Endreß B., Auge D., König J., Fromm M. F., Maas R., Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). Journal of Molecular and Cellular Cardiology 2012 53 392 400
15. Böger R. H., Endres H. G., Schwedhelm E., Darius H., Atzler D., Lüneburg N., Von Stritzky B., Maas R., Thiem U., Benndorf R. A., Diehm C., Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. Journal of Internal Medicine 2011 269 3 349 361 2-s2.0-79951693947 10.1111/j.1365-2796.2010.02322.x
16. Böger R. H., Maas R., Schulze F., Schwedhelm E., Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk. Pharmacological Research 2009 60 6 481 487 2-s2.0-70350057304 10.1016/j.phrs.2009.07.001
17. Gore M. O., Lüneburg N., Schwedhelm E., Ayers C. R., Anderssohn M., Khera A., Atzler D., de Lemos J. A., Grant P. J., McGuire D. K., Böger R. H., Symmetrical dimethylarginine predicts mortality in the general population: observations from the dallas heart study. Arteriosclerosis, Thrombosis, and Vascular Biology 2013 33 2682 2688
18. Kiechl S., Lee T., Santer P., Thompson G., Tsimikas S., Egger G., Holt D. W., Willeit J., Xu Q., Mayr M., Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009 205 1 261 265 2-s2.0-67349279132 10.1016/j.atherosclerosis. 2008.10.040
19. Lüneburg N., von Holten R.-A., Töpper R. F., Schwedhelm E., Maas R., Böger R. H., Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function. Clinical Science 2012 122 3 105 111 2-s2.0-84856404152 10.1042/CS20110013
20. Schulze F., Carter A. M., Schwedhelm E., Ajjan R., Maas R., von Holten R.-A., Atzler D., Grant P. J., Böger R. H., Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010 208 2 518 523 2-s2.0-74749108725 10.1016/j.atherosclerosis.2009.06.039
21. Hu X., Xu X., Zhu G., Atzler D., Kimoto M., Chen J., Schwedhelm E., Lüneburg N., Böger R. H., Zhang P., Chen Y., Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1- deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 2009 120 22 2222 2229 2-s2.0-73449121413 10.1161/CIRCULATIONAHA.108.819912
22. Wang D., Gill P. S., Chabrashvili T., Onozato M. L., Raggio J., Mendonca M., Dennehy K., Li M., Modlinger P., Leiper J., Vallance P., Adler O., Leone A., Tojo A., Welch W. J., Wilcox C. S., Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circulation Research 2007 101 6 627 635 2-s2.0-34748915802 10.1161/CIRCRESAHA. 107.158915 (Pubitemid 351325880)
23. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M. C., Wang B.-Y., Tsao P. S., Kimoto M., Vallance P., Patterson A. J., Cooke J. P., Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003 108 24 3042 3047 2-s2.0-0346365087 10.1161/01.CIR.0000101924.04515.2E (Pubitemid 37553576)
24. Dayoub H., Rodionov R., Cooke J. P., Lentz S. R., Faraci F. M., Human DDAH-I transgenic mice exhibit increased basal vascular NO and are protected against ADMA-induced endothelial dysfunction. The Faseb Journal 2005 19 A1238 A1238
25. Hasegawa K., Wakino S., Tatematsu S., Yoshioka K., Homma K., Sugano N., Kimoto M., Hayashi K., Itoh H., Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circulation Research 2007 101 2 e2 e10 2-s2.0-34547590325 10.1161/CIRCRESAHA.107.156901 (Pubitemid 47196589)
26. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., Patterson A. J., Kimoto M., Blau H. M., Cooke J. P., Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005 111 11 1431 1438 2-s2.0-20144362691 10.1161/01.CIR.0000158487.80483.09 (Pubitemid 40396810)
27. Konishi H., Sydow K., Cooke J. P., Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. Journal of the American College of Cardiology 2007 49 10 1099 1105 2-s2.0-33847422194 10.1016/j.jacc.2006.10.068 (Pubitemid 46349507)
28. Tanaka M., Sydow K., Gunawan F., Jacobi J., Tsao P. S., Robbins R. C., Cooke J. P., Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005 112 11 1549 1556 2-s2.0-24944522337 10.1161/CIRCULATIONAHA.105.537670 (Pubitemid 41324515)
29. Bełtowski J., Kedra A., Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports 2006 58 2 159 178 2-s2.0-33646790534
30. Yoshimatsu M., Toyokawa G., Hayami S., Unoki M., Tsunoda T., Field H. I., Kelly J. D., Neal D. E., Maehara Y., Ponder B. A. J., Nakamura Y., Hamamoto R., Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. International Journal of Cancer 2011 128 3 562 573 2-s2.0-78649638594 10.1002/ijc.25366
31. Zakrzewicz D., Eickelberg O., From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulmonary Medicine 2009 9, article 5 2-s2.0-60849089926 10.1186/1471-2466-9-5
32. Ghebremariam Y. T., Erlanson D. A., Cooke J. P., A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. Journal of Pharmacology and Experimental Therapeutics 2014 348 69 76
33. Anderssohn M., Schwedhelm E., Lüneburg N., Vasan R. S., Böger R. H., Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diabetes and Vascular Disease Research 2010 7 2 105 118 2-s2.0-77954464628 10.1177/1479164110366053
34. Böger R. H., Diemert A., Schwedhelm E., Lüneburg N., Maas R., Hecher K., The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecologic and Obstetric Investigation 2010 69 1 1 13 2-s2.0-70349894134 10.1159/000245940
35. Schwedhelm E., Böger R. H., The role of asymmetric and symmetric dimethylarginines in renal disease. Nature Reviews Nephrology 2011 7 5 275 285 2-s2.0-79955623424 10.1038/nrneph.2011.31
36. Giaid A., Saleh D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine 1995 333 4 214 221 2-s2.0-0029055964 10.1056/ NEJM199507273330403
37. Kielstein J. T., Bode-Böger S. M., Hesse G., Martens-Lobenhoffer J., Takacs A., Fliser D., Hoeper M. M., Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 7 1414 1418 2-s2.0-21544438174 10.1161/01.ATV.0000168414.06853. f0 (Pubitemid 40923361)
38. Pullamsetti S., Kiss L., Ghofrani H. A., Voswinckel R., Haredza P., Klepetko W., Aigner C., Fink L., Muyal J. P., Weissmann N., Grimminger F., Seeger W., Schermuly R. T., Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. The FASEB Journal 2005 19 9 1175 1177 2-s2.0-21744452294 10.1096/fj.04-3223fje (Pubitemid 40946456)
39. Rich S., Brundage B. H., Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. Journal of the American College of Cardiology 1989 14 3 545 550 2-s2.0-0024439748 (Pubitemid 19229324)
40. Rabinovitch M., Molecular pathogenesis of pulmonary arterial hypertension. The Journal of Clinical Investigation 2012 122 4306 4313
41. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F., Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. The American Journal of Pathology 1994 144 2 275 285 2-s2.0-0028282859 (Pubitemid 24165948)
42. Cooke J. P., A novel mechanism for pulmonary arterial hypertension? Circulation 2003 108 12 1420 1421 2-s2.0-0141615872 10.1161/01.CIR.0000087153. 11050.AB (Pubitemid 37176443)
43. Pullamsetti S. S., Savai R., Schaefer M. B., Wilhelm J., Ghofrani H. A., Weissmann N., Schudt C., Fleming I., Mayer K., Leiper J., Seeger W., Grimminger F., Schermuly R. T., CAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation 2011 123 11 1194 1204 2-s2.0-79953051762 10.1161/CIRCULATIONAHA.110.941484
44. Namkoong S., Kim C.-K., Cho Y.-L., Kim J.-H., Lee H., Ha K.-S., Choe J., Kim P.-H., Won M.-H., Kwon Y.-G., Shim E. B., Kim Y.-M., Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cellular Signalling 2009 21 6 906 915 2-s2.0-62749171705 10.1016/j.cellsig.2009.01.038
45. Galiè N., Ghofrani H. A., Torbicki A., Barst R. J., Rubin L. J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G., Sildenafil citrate therapy for pulmonary arterial hypertension. The New England Journal of Medicine 2005 353 20 2148 2157 2-s2.0-26444534291 10.1056/NEJMoa050010 (Pubitemid 41653106)
46. Ghofrani H. A., Wiedemann R., Rose F., Schermuly R. T., Olschewski H., Weissmann N., Gunther A., Walmrath D., Seeger W., Grimminger F., Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. The Lancet 2002 360 9337 895 900 2-s2.0-0037152092 10.1016/S0140-6736(02) 11024-5 (Pubitemid 35283832)
47. Wilkins M. R., Wharton J., Grimminger F., Ghofrani H. A., Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal 2008 32 1 198 209 2-s2.0-52749099087 10.1183/09031936.00124007
48. Ghofrani H. A., Grimminger F., Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. European Respiratory Review 2009 18 111 35 41 2-s2.0-61649094752 10.1183/09059180.00011112
49. Ghofrani H. A., Hoeper M. M., Halank M., Meyer F. J., Staehler G., Behrf J., Ewert R., Weimann G., Grimminger F., Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal 2010 36 4 792 799 2-s2.0-77956664858 10.1183/09031936.00182909
50. Ghofrani H. A., Galie N., Grimminger F., Riociguat for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine 2013 369 330 340
51. Ricciardolo F. L. M., Sterk P. J., Gaston B., Folkerts G., Nitric oxide in health and disease of the respiratory system. Physiological Reviews 2004 84 3 731 765 2-s2.0-2342482002 10.1152/physrev.00034.2003 (Pubitemid 38823765)
52. Robbins R. A., Barnes P. J., Springall D. R., Warren J. B., Kwon Q. J., Buttery L. D. K., Wilson A. J., Geller D. A., Polak J. M., Expression of inducible nitric oxide in human lung epithelial cells. Biochemical and Biophysical Research Communications 1994 203 1 209 218 2-s2.0-0028022515 10.1006/bbrc.1994.2169 (Pubitemid 24281081)
53. Lane C., Knight D., Burgess S., Franklin P., Horak F., Legg J., Moeller A., Stick S., Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 2004 59 9 757 760 2-s2.0-4544317836 10.1136/thx.2003.014894 (Pubitemid 39215371)
54. Maarsingh H., Bossenga B. E., Bos I. S. T., Volders H. H., Zaagsma J., Meurs H., L-Arginine deficiency causes airway hyperresponsiveness after the late asthmatic reaction. European Respiratory Journal 2009 34 1 191 199 2-s2.0-69249138275 10.1183/09031936.00105408
55. Morris C. R., Poljakovic M., Lavrisha L., Machado L., Kuypers F. A., Morris S. M. Jr., Decreased arginine bioavailability and increased serum arginase activity in asthma. The American Journal of Respiratory and Critical Care Medicine 2004 170 2 148 153 2-s2.0-3142757008 (Pubitemid 38925160)
56. Lara A., Khatri S. B., Wang Z., Comhair S. A. A., Xu W., Dweik R. A., Bodine M., Levison B. S., Hammel J., Bleecker E., Busse W., Calhoun W. J., Castro M., Kian F. C., Curran-Everett D., Gaston B., Israel E., Jarjour N., Moore W., Peters S. P., Teague W. G., Wenzel S., Hazen S. L., Erzurum S. C., Alterations of the arginine metabolome in asthma. The American Journal of Respiratory and Critical Care Medicine 2008 178 7 673 681 2-s2.0-52749084926 10.1164/rccm.200710-1542OC
57. Scott J. A., North M. L., Rafii M., Huang H., Pencharz P., Subbarao P., Belik J., Grasemann H., Asymmetric dimethylarginine is increased in asthma. The American Journal of Respiratory and Critical Care Medicine 2011 184 7 779 785 2-s2.0-80053411528 10.1164/rccm.201011-1810OC
58. Bode-Böger S. M., Scalera F., Ignarro L. J., The l-arginine paradox: importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacology and Therapeutics 2007 114 3 295 306 2-s2.0-34249706763 10.1016/j.pharmthera. 2007.03.002 (Pubitemid 46843253)
59. Klein E., Weigel J., Buford M. C., Holian A., Wells S. M., Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. The American Journal of Physiology-Lung Cellular and Molecular Physiology 2010 299 6 L816 L825 2-s2.0-78649810960 10.1152/ajplung.00188.2010
60. Ahmad T., Mabalirajan U., Ghosh B., Agrawal A., Altered asymmetric dimethyl arginine metabolism in allergically inflamed mouse lungs. The American Journal of Respiratory Cell and Molecular Biology 2010 42 1 3 8 2-s2.0-73949119562 10.1165/rcmb.2009-0137RC
61. Black P. N., Ching P. S. T., Beaumont B., Ranasinghe S., Taylor G., Merrilees M. J., Changes in elastic fibres in the small airways and alveoli in COPD. European Respiratory Journal 2008 31 5 998 1004 2-s2.0-47049094345 10.1183/09031936.00017207
62. Minai O. A., Chaouat A., Adnot S., Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. CHEST Journal 2010 137 6 39S 51S 2-s2.0-77953305629 10.1378/chest.10-0087
63. Tsoumakidou M., Tzanakis N., Chrysofakis G., Siafakas N. M., Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. CHEST Journal 2005 127 6 1911 1918 2-s2.0-21844476459 10.1378/chest.127.6.1911
64. Seimetz M., Parajuli N., Pichl A., Veit F., Kwapiszewska G., Weisel F. C., Milger K., Egemnazarov B., Turowska A., Fuchs B., Nikam S., Roth M., Sydykov A., Medebach T., Klepetko W., Jaksch P., Dumitrascu R., Garn H., Voswinckel R., Kostin S., Seeger W., Schermuly R. T., Grimminger F., Ghofrani H. A., Weissmann N., Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011 147 2 293 305 2-s2.0-80054696408 10.1016/j.cell.2011.08.035
65. di Gangi I. M., Pirillo P., Carraro S., Gucciardi A., Naturale M., Baraldi E., Giordano G., Online trapping and enrichment ultra performance liquid chromatography-tandem mass spectrometry method for sensitive measurement of, "arginine-asymmetric dimethylarginine cycle" biomarkers in human exhaled breath condensate. Analytica Chimica Acta 2012 754 67 74
66. King T. E. Jr., Pardo A., Selman M., Idiopathic pulmonary fibrosis. The Lancet 2011 378 9807 1949 1961 2-s2.0-82755161052 10.1016/S0140-6736(11)60052-4
67. Pullamsetti S. S., Savai R., Dumitrascu R., Dahal B. K., Wilhelm J., Konigshoff M., Zakrzewicz D., Ghofrani H. A., Weissmann N., Eickelberg O., Guenther A., Leiper J., Seeger W., Grimminger F., Schermuly R. T., The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Science Translational Medicine 2011 3 87 2-s2.0-79959301939 10.1126/ scitranslmed.3001725 87ra53
68. Burke A. J., Sullivan F. J., Giles F. J., Glynn S. A., The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013 34 503 512
69. Liu C.-Y., Wang C.-H., Chen T.-C., Lin H.-C., Yu C.-T., Kuo H.-P., Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. British Journal of Cancer 1998 78 4 534 541 2-s2.0-0031827486 (Pubitemid 28360645)
70. Kisley L. R., Barrett B. S., Bauer A. K., Dwyer-Nield L. D., Barthel B., Meyer A. M., Thompson D. C., Malkinson A. M., Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Research 2002 62 23 6850 6856 2-s2.0-0036896004 (Pubitemid 35424072)
71. Okayama H., Saito M., Oue N., Weiss J. M., Stauffer J., Takenoshita S., Wiltrout R. H., Hussain S. P., Harris C. C., NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. International Journal of Cancer 2013 132 9 18
72. Swinson D. E. B., Jones J. L., Richardson D., Cox G., Edwards J. G., O'Byrne K. J., Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 2002 37 3 235 240 2-s2.0-0036755102 10.1016/S0169-5002(02)00172-1 (Pubitemid 35291153)
73. Pollheimer M. J., Kornprat P., Lindtner R. A., Harbaum L., Schlemmer A., Rehak P., Langner C., Tumor necrosis is a new promising prognostic factor in colorectal cancer. Human Pathology 2010 41 12 1749 1757 2-s2.0-78449307426 10.1016/j.humpath.2010.04.018
74. Fukumura D., Kashiwagi S., Jain R. K., The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006 6 7 521 534 2-s2.0-33745559710 10.1038/nrc1910 (Pubitemid 43980541)
75. Ng Q.-S., Goh V., Milner J., Stratford M. R., Folkes L. K., Tozer G. M., Saunders M. I., Hoskin P. J., Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. The Lancet Oncology 2007 8 2 111 118 2-s2.0-33846546058 10.1016/S1470-2045(07)70001-3 (Pubitemid 46158370)
76. Tozer G. M., Prise V. E., Chaplin D. J., Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Research 1997 57 5 948 955 2-s2.0-0031018039 (Pubitemid 27098023)
77. Lévy P., Pépin J.-L., Arnaud C., Tamisier R., Borel J.-C., Dematteis M., Godin-Ribuot D., Ribuot C., Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. European Respiratory Journal 2008 32 4 1082 1095 2-s2.0-58849138380 10.1183/09031936. 00013308
78. Gozal D., Kheirandish-Gozal L., Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. The American Journal of Respiratory and Critical Care Medicine 2008 177 4 369 375 2-s2.0-39849107819 10.1164/rccm.200608-1190PP (Pubitemid 351317579)
79. Dyugovskaya L., Lavie P., Lavie L., Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. The American Journal of Respiratory and Critical Care Medicine 2002 165 7 934 939 2-s2.0-0036528981 (Pubitemid 34774660)
80. Nieto F. J., Herrington D. M., Redline S., Benjamin E. J., Robbins J. A., Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. The American Journal of Respiratory and Critical Care Medicine 2004 169 3 354 360 2-s2.0-1642537652 (Pubitemid 38134814)
81. Imadojemu V. A., Gleeson K., Quraishi S. A., Kunselman A. R., Sinoway L. I., Leuenberger U. A., Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. The American Journal of Respiratory and Critical Care Medicine 2002 165 7 950 953 2-s2.0-0036528902 (Pubitemid 34774663)
82. Ip M. S. M., Lam B., Chan L.-Y., Zheng L., Tsang K. W. T., Fung P. C. W., Lam W.-K., Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. The American Journal of Respiratory and Critical Care Medicine 2000 162 6 2166 2171 2-s2.0-0034526576 (Pubitemid 32051681)
83. Barceló A., de la Peña M., Ayllón O., Vega-Agapito M. V., Piérola J., Pérez G., González C., Alonso A., Agustí A. G. N., Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration 2009 77 85 90
84. Ohike Y., Kozaki K., Iijima K., Eto M., Kojima T., Ohga E., Santa T., Imai K., Hashimoto M., Yoshizumi M., Ouchi Y., Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure: possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circulation Journal 2005 69 2 221 226 2-s2.0-20044370806 10.1253/circj.69.221 (Pubitemid 40313045)
85. Orchard C. H., Sanchea De Leon R., Sykes M. K., The relationship between hypoxic pulmonary vasoconstriction and arterial oxygen tension in the intact dog. The Journal of Physiology 1983 338 61 74 2-s2.0-0020645222 (Pubitemid 13099476)
86. Motley H. L., Cournand A., Werko L., Himmelstein A., Dresdale D., The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man. The American Journal of Physiology 1947 150 315 320
87. Sommer N., Dietrich A., Schermuly R. T., Ghofrani H. A., Gudermann T., Schulz R., Seeger W., Grimminger F., Weissmann N., Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. European Respiratory Journal 2008 32 6 1639 1651 2-s2.0-58849142043 10.1183/09031936.00013908
88. Liu Q., Sham J. S. K., Shimoda L. A., Sylvester J. T., Hypoxic constriction of porcine distal pulmonary arteries: endothelium and endothelin dependence. The American Journal of Physiology-Lung Cellular and Molecular Physiology 2001 280 5 L856 L865 2-s2.0-0035036471
89. Aaronson P. I., Robertson T. P., Ward J. P. T., Endothelium-derived mediators and hypoxic pulmonary vasoconstriction. Respiratory Physiology & Neurobiology 2002 132 1 107 120 2-s2.0-0037158625 10.1016/S1569-9048(02)00053-8 (Pubitemid 34765693)
90. Pak O., Aldashev A., Welsh D., Peacock A., The effects of hypoxia on-the cells of the pulmonary vasculature. European Respiratory Journal 2007 30 2 364 372 2-s2.0-34547627296 10.1183/09031936.00128706 (Pubitemid 47201724)
91. Tucci M., Hammerman S. I., Furfaro S., Saukonnen J. J., Conca T. J., Farber H. W., Distinct effect of hypoxia on endothelial cell proliferation and cycling. The American Journal of Physiology-Cell Physiology 1997 272 5 C1700 C1708 2-s2.0-0030927308
92. Stenmark K. R., Fagan K. A., Frid M. G., Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation Research 2006 99 7 675 691 2-s2.0-33749345684 10.1161/01.RES.0000243584.45145.3f (Pubitemid 44498302)
93. Penaloza D., Arias-Stella J., The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007 115 9 1132 1146 2-s2.0-33947606593 10.1161/CIRCULATIONAHA.106.624544 (Pubitemid 46673174)
94. Chaouat A., Bugnet A.-S., Kadaoui N., Schott R., Enache I., Ducoloń A., Ehrhart M., Kessler R., Weitzenblum E., Severe pulmonary hypertension and chronic obstructive pulmonary disease. The American Journal of Respiratory and Critical Care Medicine 2005 172 2 189 194 2-s2.0-22144433036 10.1164/rccm.200401-006OC (Pubitemid 40981192)
95. van Eeden S., Leipsic J., Paul Man S. F., Sin D. D., The relationship between lung inflammation and cardiovascular disease. The American Journal of Respiratory and Critical Care Medicine 2012 186 11 16
96. Semenza G. L., Hypoxia-inducible factors in physiology and medicine. Cell 2012 148 3 399 408 2-s2.0-84856739946 10.1016/j.cell.2012.01.021
97. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J. M., Lane W. S., Kaelin W.G. J., HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001 292 5516 464 468 2-s2.0-0035917313 (Pubitemid 32335941)
98. Epstein A. C. R., Gleadle J. M., McNeill L. A., Hewitson K. S., O'Rourke J., Mole D. R., Mukherji M., Metzen E., Wilson M. I., Dhanda A., Tian Y.-M., Masson N., Hamilton D. L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P. H., Pugh C. W., Schofield C. J., Ratcliffe P. J., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001 107 1 43 54 2-s2.0-17944375360 10.1016/S0092-8674(01) 00507-4 (Pubitemid 32972036)
99. Kaelin W. G. Jr., Ratcliffe P. J., Oxygen sensing by metazoans: the central role of the hif hydroxylase pathway. Molecular Cell 2008 30 4 393 402 2-s2.0-43649093915 10.1016/j.molcel.2008.04.009 (Pubitemid 351681994)
100. Haase V. H., Regulation of erythropoiesis by hypoxia-inducible factors. Blood Reviews 2013 27 41 53
101. Gao L., Chen Q., Zhou X., Fan L., The role of hypoxia-inducible factor 1 in atherosclerosis. Journal of Clinical Pathology 2012 65 872 876 2-s2.0-84860621646 10.1136/jclinpath-2012-200828
102. Germani A., di Campli C., Pompilio G., Biglioli P., Capogrossi M. C., Regenerative therapy in peripheral artery disease. Cardiovascular Therapeutics 2009 27 4 289 304 2-s2.0-70449499017 10.1111/j.1755-5922.2009.00105.x
103. Robinson A., Keely S., Karhausen J., Gerich M. E., Furuta G. T., Colgan S. P., Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008 134 1 145 155 2-s2.0-37349048502 10.1053/j.gastro.2007.09.033 (Pubitemid 350309309)
104. Wilkes D. S., Chronic lung allograft rejection and airway microvasculature: is HIF-1 the missing link? The Journal of Clinical Investigation 2011 121 6 2155 2157 2-s2.0-79957895001 10.1172/JCI58329
105. Tsai Y.-P., Wu K.-J., Hypoxia-regulated target genes implicated in tumor metastasis. Journal of Biomedical Science 2012 19, article 102
106. Bond J., Gale D. P., Connor T., Adams S., De Boer J., Gascoyne D. M., Williams O., Maxwell P. H., Ancliff P. J., Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood 2011 117 13 3699 3701 2-s2.0-79953695043 10.1182/blood-2010-12-327569
107. Garvey J. F., Taylor C. T., McNicholas W. T., Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. European Respiratory Journal 2009 33 5 1195 1205 2-s2.0-66749190028 10.1183/09031936.00111208
108. Foster M. W., McMahon T. J., Stamler J. S., S-nitrosylation in health and disease. Trends in Molecular Medicine 2003 9 4 160 168 2-s2.0-0038136867 10.1016/S1471-4914(03)00028-5 (Pubitemid 36626705)
109. Palmer L. A., Doctor A., Chhabra P., Sheram M. L., Laubach V. E., Karlinsey M. Z., Forbes M. S., Macdonald T., Gaston B., S-Nitrosothiols signal hypoxia-mimetic vascular pathology. The Journal of Clinical Investigation 2007 117 9 2592 2601 2-s2.0-34848881907 10.1172/JCI29444 (Pubitemid 47494360)
110. Li F., Sonveaux P., Rabbani Z. N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M., Li C.-Y., Regulation of HIF-1 α stability through S-nitrosylation. Molecular Cell 2007 26 1 63 74 2-s2.0-34047272690 10.1016/j.molcel.2007.02.024 (Pubitemid 46550936)
111. Mateo J., García-Lecea M., Cadenas S., Hernández C., Moncada S., Regulation of hypoxia-inducible factor-1 α by nitric oxide through mitochondria-dependent and -independent pathways. Biochemical Journal 2003 376 2 537 544 2-s2.0-0346027211 10.1042/BJ20031155 (Pubitemid 38010539)
112. Hagen T., Taylor C. T., Lam F., Moncada S., Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1 α Science 2003 302 5652 1975 1978 2-s2.0-0348134741 10.1126/science.1088805 (Pubitemid 37523507)
113. Chowdhury R., Flashman E., Mecinović J., Kramer H. B., Kessler B. M., Frapart Y. M., Boucher J.-L., Clifton I. J., McDonough M. A., Schofield C. J., Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1). Journal of Molecular Biology 2011 410 2 268 279 2-s2.0-79958716098 10.1016/j.jmb.2011.04.075
114. Block E. R., Herrera H., Couch M., Hypoxia inhibits L-arginine uptake by pulmonary artery endothelial cells. The American Journal of Physiology-Lung Cellular and Molecular Physiology 1995 269 5 L574 L580 2-s2.0-0028827584 (Pubitemid 3005927)
115. Maas R., Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vascular Medicine 2005 10 2, supplement S49 S57 2-s2.0-31344440297 10.1191/1358863x05vm605oa (Pubitemid 43137268)
116. Murray-Rust J., Leiper J., McAlister M., Phelan J., Tilley S., Santa Maria J., Vallance P., McDonald N., Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nature Structural & Molecular Biology 2001 8 679 683 (Pubitemid 32757926)
117. Leiper J., Murray-Rust J., McDonald N., Vallance P., S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13527 13532 2-s2.0-0037108966 10.1073/pnas.212269799 (Pubitemid 35215415)
118. Bakr A., Pak O., Taye A., Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. The American Journal of Respiratory Cell and Molecular Biology 2013 49 491 500
119. Ito A., Tsao P. S., Adimoolam S., Kimoto M., Ogawa T., Cooke J. P., Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999 99 24 3092 3095 2-s2.0-0033594888 (Pubitemid 29289071)
120. Lin K. Y., Ito A., Asagami T., Tsao P. S., Adimoolam S., Kimoto M., Tsuji H., Reaven G. M., Cooke J. P., Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002 106 8 987 992 2-s2.0-0037143637 10.1161/01.CIR.0000027109.14149.67 (Pubitemid 34925335)
121. Sydow K., Münzel T., ADMA and oxidative stress. Atherosclerosis Supplements 2003 4 4 41 51 2-s2.0-1242273844 10.1016/S1567-5688(03)00033-3 (Pubitemid 38234494)
122. Ivashchenko C. Y., Bradley B. T., Ao Z., Leiper J., Vallance P., Johns D. G., Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. The American Journal of Physiology-Heart and Circulatory Physiology 2010 298 1 H251 H258 2-s2.0-73549110255 10.1152/ajpheart.00195.2009
123. Hasegawa K., Wakino S., Tanaka T., Kimoto M., Tatematsu S., Kanda T., Yoshioka K., Homma K., Sugano N., Kurabayashi M., Saruta T., Hayashi K., Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 7 1488 1494 2-s2.0-33745953244 10.1161/01.ATV.0000219615.88323.b4 (Pubitemid 44288973)
124. Jung C. H., Lee W. J., Hwang J. Y., Lee M. J., Seol S. M., Kim Y. M., Lee Y. L., Kim H. S., Kim M. S., Park J. Y., Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS ONE 2012 7 e52346
125. Eikelboom J. W., Lonn E., Genest J. Jr., Hankey G., Yusuf S., Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Annals of Internal Medicine 1999 131 5 363 375 2-s2.0-0033533527 (Pubitemid 29424631)
126. Zhang J.-G., Liu J.-X., Li Z.-H., Wang L.-Z., Jiang Y.-D., Wang S.-R., Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chinese Medical Journal 2007 120 23 2132 2137 2-s2.0-37249061193 (Pubitemid 350268163)
127. Janssen W., Pullamsetti S. S., Cooke J., Weissmann N., Guenther A., Schermuly R. T., The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. The Journal of Pathology 2013 229 242 249
128. Nandi M., Kelly P., Torondel B., Wang Z., Starr A., Ma Y., Cunningham P., Stidwill R., Leiper J., Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 2589 2597